Several previous studies have investigated the serum/urinary levels of KIM‐1 in patients with ccRCC to improve the implementation of treatment strategies, including early detection and risk stratification of diseases [11, 12, 18, 34]. This evidence concerns the gene HAVCR1 and nonpapillary renal cell carcinoma.